Takeda has licensed a biodegradable polymer and a linker platform from Mersana to further move forward its ADC program aimed at various cancers. The program will mainly complement Takeda's Millenium Pharmaceuticals (MP) development pipeline.
The so-called Fleximer ADC Technology platform from Mersana will allow MP to take its antibodies and conjugae to Mersana cytotoxic drugs. The platform is customizable and offers users advantages like increased drug loads per antibody, use with antibody fragments, and the ability to deliver anti-tubulin agents. The advantages derive from the biodegrable polymers used and to the customizable linker chemistries available.
The linkers can be customized to do things like control rate of drug release, mechanism of release, localization of drug release, delivery of multiple agents, improving biodistribution, altering pharmacokinetics and changing half-life.
Takeda announced earlier this week another deal with Trianni's mouse monoclonal antibody discovery platform and this will be complementary with the Mersana technology. Mersana is set to receive milestones and royalties from the deal as drugs are commercialized. See Biopharma-Reporter.
Posted by Bruce Lehr April 9th 2014